Peritoneal dialysis first policy in Hong Kong for 35 years: Global impact.


Journal

Nephrology (Carlton, Vic.)
ISSN: 1440-1797
Titre abrégé: Nephrology (Carlton)
Pays: Australia
ID NLM: 9615568

Informations de publication

Date de publication:
Oct 2022
Historique:
revised: 28 03 2022
received: 07 03 2022
accepted: 04 04 2022
pubmed: 9 4 2022
medline: 23 9 2022
entrez: 8 4 2022
Statut: ppublish

Résumé

Peritoneal dialysis (PD) first policy has been established in Hong Kong since 1985. After 35 years of practice, the PD first policy in Hong Kong has influenced many countries around the world including governments, health ministries, nephrologists and renal nurses on the overall health policy structure and clinical practice in treating kidney failure patients using PD as an important dialysis modality. In 2021, the International Association of Chinese Nephrologists and the Hong Kong Society of Nephrology jointly held a symposium celebrating the 35 years of PD first policy in Hong Kong. In that symposium, experts and opinion leaders from around the world have shared their perspectives on how the PD first policy has grown and how it has affected PD and home dialysis practice globally. The advantages of PD during COVID-19 pandemic were highlighted and the use of telemedicine as an important adjunct was discussed in treating kidney failure patients to improve the overall quality of care. Barriers to PD and the need for sustainability of PD first policy were also emphasized. Overall, the knowledge awareness of PD as a home dialysis for patients, families, care providers and learners is a prerequisite for the success of PD first. A critical mass of PD regional hubs is needed for training and mentorship. Importantly, the alignment of policy and clinical goals are enablers of PD first program.

Identifiants

pubmed: 35393750
doi: 10.1111/nep.14042
pmc: PMC9790333
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

787-794

Informations de copyright

© 2022 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.

Références

Nat Rev Nephrol. 2010 Feb;6(2):75-82
pubmed: 20010897
Kidney Int Suppl (2011). 2015 Jun;5(1):33-38
pubmed: 26097783
J Nephrol. 2020 Aug;33(4):725-736
pubmed: 32621109
J Diabetes Investig. 2021 Mar;12(3):346-356
pubmed: 32654341
Am J Kidney Dis. 2019 Mar;73(3):363-371
pubmed: 30545707
Am J Kidney Dis. 2015 Jan;65(1):147-51
pubmed: 25446022
Nat Rev Nephrol. 2013 Sep;9(9):523-8
pubmed: 23877587
Perit Dial Int. 2007 Jun;27 Suppl 2:S153-7
pubmed: 17556295
Kidney360. 2020 May 13;1(7):680-684
pubmed: 35372929
Contrib Nephrol. 2019;197:54-64
pubmed: 34569514
Nephrology (Carlton). 2022 Oct;27(10):787-794
pubmed: 35393750
Lancet. 2012 Mar 3;379(9818):815-22
pubmed: 22386035
Kidney Blood Press Res. 2021;46(1):11-16
pubmed: 33517338
Int Urol Nephrol. 2010 Sep;42(3):759-64
pubmed: 20563843
Am J Kidney Dis. 2021 Jan;77(1):142-148
pubmed: 33002530
Nephrol Dial Transplant. 2019 Nov 1;34(11):1941-1949
pubmed: 31329952
Perit Dial Int. 2007 Jun;27 Suppl 2:S53-5
pubmed: 17556329
Blood Purif. 2015;40(4):320-5
pubmed: 26657278
Am J Kidney Dis. 2021 May;77(5):748-756.e1
pubmed: 33465417
Perit Dial Int. 2015 Jul-Aug;35(4):406-20
pubmed: 25082840
Kidney Dis (Basel). 2015 Dec;1(3):147-56
pubmed: 27536675
Perit Dial Int. 2007 Jun;27 Suppl 2:S59-61
pubmed: 17556331
J Med Ethics. 1986 Jun;12(2):61-3
pubmed: 3735359
Int J Nephrol. 2011;2011:434608
pubmed: 22121484
Kidney Dis (Basel). 2021 May;7(3):167-175
pubmed: 34179112
Am J Kidney Dis. 2013 Nov;62(5):993-1005
pubmed: 23751775
Perit Dial Int. 2008 Jun;28 Suppl 3:S53-8
pubmed: 18552265
Kidney Med. 2019 Oct 17;1(6):354-365
pubmed: 32734216
Perit Dial Int. 2007 Sep-Oct;27(5):489-95
pubmed: 17704434
Perit Dial Int. 2011 Mar-Apr;31(2):121-6
pubmed: 21193551
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Semin Nephrol. 2017 May;37(3):287-295
pubmed: 28532557
Transplant Proc. 1999 Dec;31(8):3275-7
pubmed: 10616473
Kidney Int Rep. 2020 Aug 26;5(11):1965-1973
pubmed: 33163717
Am J Kidney Dis. 2020 Jun;75(6):926-934
pubmed: 32057468
Nephrol Dial Transplant. 2008 May;23(5):1475-8
pubmed: 18303111
Am J Nephrol. 2020;51(6):480-482
pubmed: 32344420

Auteurs

Philip Kam-Tao Li (PK)

Department of Medicine and Therapeutics, Carol and Richard Yu Peritoneal Dialysis Research Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, SAR, China.

Wanhong Lu (W)

Department of Nephrology, Kidney Hospital, The First Affiliated Hospital of Xi'an, Jiaotong University, Xi'an, China.

Siu-Ka Mak (SK)

Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong, SAR, China.

Neil Boudville (N)

Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

Xueqing Yu (X)

Department of Nephrology, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.

Ming Ju Wu (MJ)

Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

Yuk-Lun Cheng (YL)

Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong.

Christopher T Chan (CT)

Division of Nephrology, University Health Network, Toronto, Ontario, Canada.

Bak Leong Goh (BL)

Department of Nephrology, Hospital Serdang, Kajang, Selangor, Malaysia.

Na Tian (N)

Department of Nephrology, General Hospital of Ningxia Medical University, Ningxia, China.

Kai Ming Chow (KM)

Department of Medicine and Therapeutics, Carol and Richard Yu Peritoneal Dialysis Research Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, SAR, China.

Sing Leung Lui (SL)

Department of Medicine, Tung Wah Hospital, Hong Kong.

Wai Kei Lo (WK)

Dialysis Centre, Gleneagles Hospital, Hong Kong, SAR, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH